Post-Herpetic Neuralgia Treatment on the GST Road — Burning Nerve Pain After Shingles, Finally Addressed

You were probably told the pain would ease as the nerve healed. You may have been told to give it more time. Perhaps you have given it six months. A year. Longer.

Post-herpetic neuralgia that persists beyond three months without adequate treatment is unlikely to resolve fully on its own. For patients over 65, if the pain has persisted beyond twelve months, it is likely to become a permanent condition without targeted nerve intervention.

This is not said to alarm you. It is said so that you understand why continuing to wait — and continuing to manage with tablets that cause drowsiness and weight gain — is not your only option.

The nerve damage that causes PHN is real, measurable, and — in a significant proportion of patients — responsive to the targeted interventional procedures available at Dr. RRB Pain Care.

The earlier specialist intervention begins, the better the outcomes. But even in long-standing PHN, meaningful pain reduction is achievable for most patients.

Post-herpetic neuralgia (PHN) is a chronic nerve pain condition characterised by focal nerve pain that occurs or persists for 90 days or more after the onset of a shingles (herpes zoster) episode — even after the rash and blisters have completely healed.

PHN is the most common complication of shingles. It affects approximately 10–20% of all individuals who develop shingles — and among those aged 60 and above, up to 50% may experience PHN following a shingles outbreak. In patients who are 80 and older, 50% of those who develop shingles will still have pain one year later.

Understanding why PHN hurts the way it does — even when the virus is no longer active — is critical to understanding why the pain requires specific targeted treatment rather than simply time.

During a shingles outbreak, the varicella-zoster virus reactivates from its dormant state within the dorsal root ganglia — the clusters of sensory nerve cell bodies that sit adjacent to the spinal cord and contain the nerve roots that supply sensation to specific areas of the body.

The dorsal root ganglion itself — the nerve cell bodies sustain injury from the viral infection, disrupting their normal signalling function

The peripheral sensory nerve fibres — travelling from the ganglion to the skin, these fibres are damaged, demyelinated, and structurally disrupted by the viral inflammation

The central pain processing pathways — the sustained abnormal input from damaged peripheral nerves sensitises the dorsal horn of the spinal cord, establishing central sensitisation

The result of this triple injury is a nerve that has lost its normal signal filtering capacity. It can no longer distinguish painful stimuli from non-painful ones. Stimuli that should not produce pain — gentle touch, the weight of fabric, a change in air temperature — are transmitted as intense pain signals. Spontaneous, unprovoked pain arises from the damaged nerve firing without any external stimulus at all.

This pathological nerve behaviour — not the virus, which is no longer active — is what generates the burning, electric, stabbing pain of PHN. And because it is a result of structural nerve damage rather than active infection, antiviral medication given after the fact has no effect on it.

PHN is a textbook neuropathic pain condition — pain arising from damage to or dysfunction of the nervous system itself, rather than from ongoing tissue injury. This classification is clinically important because it explains:

Why the pain responds to specific neuropathic agents — pregabalin, gabapentin, amitriptyline, duloxetine

Why targeted nerve procedures that modify the abnormal nerve signalling are the most effective interventional approach

Why central sensitisation must be addressed as part of any comprehensive treatment plan

Shingles is a painful viral illness caused by the reactivation of the varicella-zoster virus — the same virus that causes chickenpox. After chickenpox resolves, the virus does not leave the body. It travels along nerve fibres to the dorsal root ganglia, where it lies dormant — sometimes for decades.

Under conditions of reduced immunity — advancing age, chronic illness, immunosuppressive medication, cancer treatment, extreme stress — the virus reactivates, travels back along the nerve to the skin, and produces the characteristic shingles rash: a painful, blistering eruption confined to one side of the body in the territory of a specific nerve root or cranial nerve.

Thoracic dermatomes (chest, trunk, back) — the most common location. About 65% of patients report continuous, stabbing thoracic pain between the neck and the abdomen. The pain follows a band-like distribution around one side of the chest or abdomen — following the path of the affected intercostal nerve.

Ophthalmic (forehead, eye, upper face) — about 20% of patients report pain in the face, usually above the eyebrows — in the territory of the ophthalmic branch of the trigeminal nerve. This presentation, called herpes zoster ophthalmicus, has a significantly higher rate of PHN development and can be particularly severe.

Cervical and lumbar dermatomes — neck, shoulder, arm, lower back, or leg involvement depending on the affected nerve root level.

Ramsay Hunt syndrome — rare but important: shingles affecting the facial nerve and geniculate ganglion, causing ear pain, facial palsy, and PHN in the ear, face, and neck.

Not everyone who has shingles develops PHN. The following factors significantly increase the risk:

The risk of PHN increases dramatically with age. PHN is uncommon in patients under 40, moderately common in those 40–59, and highly prevalent in patients 60 and above. Among those over 80, the majority who develop shingles will experience PHN — and the pain is typically more severe and more persistent than in younger patients.

The reason is age-related decline in both immune function — which allows more severe viral reactivation — and neural repair capacity — which reduces the nerve's ability to recover from the viral damage.

Diabetic patients have compromised peripheral nerve health at baseline — from the glycaemic injury of long-standing diabetes. When shingles damages an already-vulnerable nerve system, the resulting PHN is typically more severe and slower to resolve. Diabetes is highly prevalent in the GST Road corridor population — Kattankulathur, Tambaram, Chengalpattu — and diabetic PHN patients represent a significant proportion of those seen at Dr. RRB Pain Care.

The more severe the shingles — the more extensive the rash, the more intense the acute pain — the greater the nerve damage, and the higher the risk of persistent PHN. A prodromal pain phase before the rash appeared also increases PHN risk.

Shingles affecting the forehead, scalp, and eye region carries a higher PHN risk than thoracic shingles — because the trigeminal nerve and its ganglion (the Gasserian ganglion) have particularly high viral latency and a complex central pain processing relationship.

Patients on immunosuppressive medications (post-organ transplant, rheumatological disease management), those receiving chemotherapy, and those with HIV or haematological malignancies are at significantly elevated risk of shingles reactivation and subsequent PHN.

PHN is one of the most distinctively described pain conditions in medicine. Patients use remarkably consistent language to describe it:

A deep, continuous burning or scalding sensation in the area of the previous shingles rash. This is the hallmark symptom — described as feeling like "the skin is on fire," "a hot iron pressed against the skin," or "acid burning underneath." The pain is typically present continuously, varying in intensity rather than fully resolving between episodes.

Sudden, brief, intensely sharp stabbing or electric shock-like pains that shoot through the affected area without warning. These lancinating pains overlay the background burning — arriving unpredictably and with extraordinary intensity. Patients describe them as "lightning bolts," "knife stabs," or "electric shocks."

Pain from stimuli that should not be painful. This is the feature of PHN that most severely affects daily life and is the most important for family members and caregivers to understand.

In allodynia, the damaged nerve has lost its ability to filter non-painful stimuli. The weight of a bedsheet, the touch of a cotton shirt, the movement of air across the skin, a gentle hand on the shoulder — all of these trigger intense pain.

For thoracic PHN patients, wearing any clothing over the affected area becomes intolerable. For ophthalmic PHN patients, eyeglasses touching the face become unbearable. Bathing the affected area, sleeping on the affected side, and being touched by family members all become sources of severe pain.

The social and relational consequences of allodynia are profound — and frequently underestimated by treating physicians who focus on pain scores rather than functional impact.

Stimuli that are mildly painful in normal circumstances produce dramatically amplified pain in PHN. A light scratch that would normally register as mild discomfort becomes severe pain. Temperature changes — cool air, cold water — trigger disproportionate pain responses.

Many PHN patients experience a paradoxical combination of increased pain sensitivity alongside areas of numbness and reduced sensation — reflecting the mixed population of damaged and hypersensitised nerve fibres in the affected territory. An intense, deep itch — impossible to scratch because scratching worsens the pain — is a particularly distressing feature for some patients.

PHN is not simply a pain condition. It is a condition that destroys quality of life across multiple domains simultaneously:

Sleep — the burning and lancinating pain is consistently worse at rest and at night, making sustained sleep impossible for many patients. Chronic sleep deprivation compounds all other symptoms.

Appetite — chronic pain suppresses appetite, and many patients lose significant weight during prolonged PHN.

Mood — depression is documented in approximately 40–50% of PHN patients. The combination of constant severe pain, social isolation (from allodynia preventing contact), sleep deprivation, and medication side effects drives a significant mood disorder in many patients.

Independence — the inability to dress, bathe, or be touched without pain progressively reduces independence and increases caregiver burden on family members.

Post-herpetic neuralgia requires no laboratory tests or imaging for diagnosis. It is a clinical diagnosis based on:

History: A documented or reported episode of shingles (herpes zoster) in the past — confirmed either by the characteristic rash, a medical record of the episode, or the patient's clear recall of the blistering eruption in a dermatomal distribution.

Pain duration: Pain persisting in the same anatomical area for 90 days or more after the shingles onset — the internationally agreed diagnostic timeframe for PHN.

Neurological assessment: Systematic sensory examination of the affected area — documenting the pattern of allodynia (distribution of touch-triggered pain), hyperalgesia (extent of amplified pain response), and areas of numbness. This sensory mapping guides the selection of targeted treatment.

Severity grading: PHN is graded by pain intensity, allodynia severity, functional impact, and medication history — all of which influence the most appropriate interventional approach.

Imaging: MRI of the relevant spinal level or trigeminal nerve pathway may be performed in atypical or complex cases to exclude coexisting structural pathology. It is not required for standard PHN diagnosis.

Medication Management — What Works, What Doesn't, and Why Intervention Becomes Necessary:

Medical management is the appropriate starting point for PHN — and for many patients with mild to moderate disease, a well-optimised medication regimen provides meaningful relief. However, for a significant proportion of patients, medications provide only partial relief — and carry side effects that reduce quality of life as much as the pain itself.

Pregabalin and Gabapentin — alpha-2-delta calcium channel modulators that reduce the abnormal pain signalling in sensitised nociceptors. The most commonly prescribed medications for PHN. Effective for many patients at appropriate doses but produce drowsiness, cognitive blunting, weight gain, and peripheral oedema — particularly at the higher doses required for adequate PHN control in older patients.

Tricyclic Antidepressants (Amitriptyline, Nortriptyline) — modulate central pain processing through multiple mechanisms. Evidence-supported for PHN but produce significant anticholinergic side effects (dry mouth, urinary retention, constipation, confusion) that limit their use in elderly patients.

SNRIs (Duloxetine) — dual-action antidepressants with analgesic properties. Better tolerated than tricyclics in older patients.

Lidocaine 5% Patch — applied directly to the allodynic skin, the patch delivers local anaesthetic to the sensitised peripheral nerve endings without systemic absorption. Extremely well tolerated — no systemic side effects. Provides meaningful allodynia relief in patients with predominantly cutaneous hypersensitivity. Suitable for all age groups including frail elderly patients.

Capsaicin 8% Patch (High-Concentration) — a single topical application of high-concentration capsaicin depletes Substance P from the peripheral nociceptors in the treated area — producing meaningful pain reduction lasting 3–4 months from a single treatment session. Particularly effective for well-localised allodynia in thoracic PHN.

Moderate to severe pain rated 5/10 or above despite optimised medication

Intolerable medication side effects that prevent dose escalation to therapeutic levels

Long-standing PHN (more than 12 months) that has not responded to multiple medication trials

PHN in the ophthalmic distribution — which tends to be more refractory to standard medication

...reach a point where targeted interventional procedures offer the next meaningful step forward.

For PHN affecting the chest, trunk, or abdomen — the most common anatomical location — the intercostal nerve block delivers a targeted combination of local anaesthetic and corticosteroid to the specific intercostal nerve carrying the abnormal pain signals from the affected dermatome.

The intercostal nerve travels in the groove along the underside of each rib — and an ultrasound-guided injection precisely targets this specific nerve, delivering medication at the site of ongoing nociceptor activity in the peripheral nerve.

Immediate interruption of the abnormal pain signal from the affected intercostal nerve

Reduction in allodynia — the touch-triggered pain that makes clothing and bedsheets unbearable

A therapeutic window during which central sensitisation can begin to unwind

The procedure is performed under real-time ultrasound guidance at Dr. RRB Pain Care — confirming the needle is adjacent to the target nerve before any medication is injected.

Duration of relief: Variable — from several weeks to several months. Often repeated at intervals as part of a planned treatment programme. Most effective when combined with optimised medical management.

Greater Occipital Nerve Block and Supraorbital Nerve Block — For Facial and Ophthalmic PHN:

For PHN affecting the forehead, scalp, eye region, and periorbital area — the ophthalmic distribution, which accounts for approximately 20% of all PHN cases — nerve blocks targeting the greater occipital nerve (posterior scalp) and supraorbital nerve (forehead, upper face) interrupt the peripheral pain signals from these affected nerve territories.

These blocks are performed under ultrasound guidance to confirm precise peri-neural placement — the supraorbital notch is clearly visible on ultrasound, allowing accurate delivery adjacent to the nerve without risk to the eye.

Who this is for: Patients with PHN-related forehead and scalp burning, allodynia of the scalp (unable to wash or comb hair), periorbital pain, and pain aggravated by wearing glasses.

Pulsed Radiofrequency of the Dorsal Root Ganglion (DRG-PRF) — The Most Advanced Non-Destructive Intervention:

For refractory thoracic, cervical, or lumbar PHN that has not responded adequately to medication and peripheral nerve blocks, Pulsed Radiofrequency (PRF) treatment of the Dorsal Root Ganglion represents the most advanced non-destructive interventional option available.

The dorsal root ganglion is the cluster of sensory nerve cell bodies that sits in the intervertebral foramen — the bony channel through which the nerve root exits the spine. In PHN, it is the DRG at the affected level that was directly damaged by the varicella-zoster virus during the shingles episode. The ongoing pathological activity of the damaged DRG cell bodies is a major driver of the persistent PHN pain signal.

Unlike conventional radiofrequency ablation — which uses sustained thermal energy to destroy nerve function — pulsed radiofrequency delivers brief, intermittent pulses of radiofrequency electromagnetic energy to the DRG. This modulates the electrical activity of the damaged ganglion cells — reducing their aberrant firing — without destroying them.

This is an important distinction: DRG-PRF is non-destructive. It modulates, rather than ablates. It does not permanently damage the nerve cell bodies. This makes it appropriate for a sensory nerve structure like the DRG — where preserving nerve function while reducing abnormal activity is the goal.

The procedure is performed under fluoroscopic guidance at Dr. RRB Pain Care — the needle is precisely advanced to the DRG at the affected spinal level using the same approach as a transforaminal epidural, with contrast confirmation of DRG position before radiofrequency delivery.

Clinical outcomes: Studies of DRG-PRF for PHN consistently show meaningful, sustained pain reduction — with the majority of patients reporting significant improvement at 3 and 6 months. The procedure can be safely repeated.

For patients with severe, established PHN that has not responded adequately to multiple medications, nerve blocks, and DRG-PRF, Spinal Cord Stimulation (SCS) represents the next tier of management.

SCS delivers electrical stimulation to the dorsal columns of the spinal cord at the affected level — modulating the central pain processing pathways that have become sensitised in chronic PHN. The mechanism of SCS in PHN involves gate control modulation and suppression of the abnormal central sensitisation that perpetuates the pain cycle.

A trial stimulation period is conducted before any permanent implantation — allowing the patient to experience the potential benefit before committing to the definitive procedure. Dr. RRB coordinates the SCS pathway with appropriate neurosurgical colleagues for implantation.

For patients with severe allodynia, protecting the affected area while gradually reducing its hypersensitivity is an important component of daily management:

Protective soft dressings — silicone or foam-backed dressings over the most allodynic areas prevent constant clothing stimulation without applying adhesive to the sensitive skin

Graded desensitisation — a structured programme of progressively increasing tactile stimulation to the affected area — beginning with the lightest materials (a piece of silk fabric moved over the area at a set distance) and slowly working toward normal contact tolerance over weeks. This must be conducted very gradually and within pain tolerance.

Thermal modification — some patients find cold packs provide temporary relief; others find mild warmth helpful. Identifying which modality reduces symptoms guides the use of topical thermal therapy

Depression and anxiety are documented in approximately 40–50% of PHN patients. The interaction between chronic pain, sleep deprivation, and mood disorder creates a cycle in which each component worsens the others. Psychological support — cognitive behavioural therapy for chronic pain specifically — is an evidence-supported adjunct to medical and interventional treatment that significantly improves overall outcomes.

Dr. RRB coordinates referral to psychological support services where appropriate — recognising that pain management and psychological wellbeing are inseparable in chronic PHN management.

PHN-disrupted sleep is not simply a consequence of pain — the sleep disruption itself lowers the pain threshold, creating a vicious cycle. Addressing sleep directly — through low-dose amitriptyline or mirtazapine at night, sleep hygiene measures, and where necessary, referral to sleep medicine — is an integral part of comprehensive PHN management.

Many PHN patients are already under the care of a dermatologist (who managed the acute shingles), an ophthalmologist (for ophthalmic herpes zoster), or a general physician. Dr. RRB Pain Care works alongside these teams — not instead of them — ensuring that the pain management component is integrated with, and communicates with, the broader care plan.

Why Patients from Kattankulathur, Tambaram, and Across the GST Road Corridor Choose Dr. RRB Pain Care for PHN:

Post-herpetic neuralgia — particularly in its severe and refractory forms — requires a pain specialist trained specifically in advanced interventional neuropathic pain procedures. Intercostal nerve blocks, DRG pulsed radiofrequency, and spinal cord stimulation pathway coordination are not skills available at general pain clinics. Dr. RajaRajan Balasubramanian's FIPP certification specifically validates competency in these advanced procedures to international standards.

PHN predominantly affects patients over 60. Many of these patients also have comorbidities — diabetes, cardiovascular disease, hypertension, kidney impairment — that influence medication choices and procedural risk assessment. Dr. RRB's treatment plans for elderly PHN patients are specifically adapted to these comorbidities — selecting medications that are appropriate for renal function, coordinating with cardiologists where needed, and performing procedures with the patient's overall clinical status fully considered.

PHN is one of the most challenging chronic pain conditions in medicine — and it demands honesty. At Dr. RRB Pain Care, the consultation begins with a frank discussion of what interventional treatment can realistically achieve for your specific degree of nerve damage, duration of pain, and current functional status. Realistic goals — meaningful pain reduction, improved sleep, reduced medication burden, better tolerated clothing and touch — are achievable for most patients. Complete elimination of all pain is possible for some but cannot be guaranteed for all. Transparency about outcomes is the foundation of trust at this clinic.

Kattankulathur: 10–15 minutes

Maraimalai Nagar / SP Koil: 5–10 minutes

Oragadam: 20–25 minutes

Guduvancheri: 15–20 minutes

Tambaram: 25–30 minutes

Chengalpattu: 30–35 minutes

Mahindra World City: 10–15 minutes

The recombinant herpes zoster vaccine (Shingrix) is approximately 90% effective in preventing shingles — and significantly reduces PHN risk in those who still develop shingles despite vaccination.

All adults over 50 years of age — regardless of prior chickenpox or shingles history

Adults over 18 with immunocompromising conditions — on a case-by-case basis with their physician

Even adults who have already had shingles — to prevent recurrence

For patients in the Kancheepuram district and the GST Road corridor over 50 who have not yet been vaccinated, this is the single most important preventive step. A single bout of PHN will affect quality of life far more severely than the cost and minimal discomfort of the two-dose vaccine course.

Pain in the area of a previous shingles rash has persisted for more than 3 months — this meets the definition of PHN and warrants specialist evaluation

The pain is rated 5/10 or above and is significantly affecting sleep, daily function, or quality of life

Allodynia — pain from clothing, touch, or air movement over the affected area — is a dominant feature

Medications have provided partial but not adequate relief — or medication side effects are limiting your ability to take a therapeutic dose

You have PHN in the ophthalmic zone — forehead, eye area, scalp — which requires specialist assessment

Pain has persisted for more than 12 months — the window for good outcomes with intervention narrows over time, but meaningful improvement remains achievable with targeted procedures

You are a family member or caregiver of an elderly patient with PHN and want specialist guidance on what treatment options remain

A note for caregivers: If your parent or family member has been living with burning, persistent pain for months after shingles and has been told to "wait and see" — a specialist consultation is worthwhile. The pain they are experiencing is real, it is clinically documented, and targeted interventional treatment can meaningfully reduce it in most cases.

PHN pain persists for more than three months after shingles in 10–20% of all shingles patients. Many people with PHN make a full recovery within a year of developing the condition — particularly with appropriate specialist management. However, for patients over 65, if pain persists beyond twelve months it is likely to become a long-term condition without targeted nerve intervention. The duration is strongly influenced by age at onset, severity of the original shingles episode, how quickly antiviral treatment was started, and how early and appropriately the PHN itself is treated. Early specialist intervention produces consistently better outcomes than waiting.

The burning, electric pain and the sensitivity to touch that follows shingles are caused by damage to the sensory nerve fibres and the dorsal root ganglion — the cluster of nerve cell bodies adjacent to the spinal cord — during the viral infection. This damage disrupts the nerve's normal pain-filtering mechanism. Stimuli that should not be painful — the touch of fabric, a change in air temperature — are transmitted as intense pain signals because the nerve can no longer distinguish them from genuinely harmful stimuli. This phenomenon is called allodynia. It is a direct consequence of the nerve damage from the varicella-zoster virus — not psychological, and not something that should be dismissed as "just sensitivity."

Pulsed radiofrequency (PRF) of the dorsal root ganglion delivers brief, intermittent electromagnetic pulses to the ganglion at the affected spinal level — modulating the abnormal electrical activity of the damaged nerve cell bodies without destroying them. Unlike conventional radiofrequency ablation, PRF is non-destructive — it does not permanently damage the nerve. The procedure is performed under fluoroscopic guidance with contrast confirmation of needle position at the DRG before any radiofrequency energy is applied. It is safe, minimally invasive, and has a good evidence base for PHN pain reduction with benefits documented at 3 and 6 months. The procedure takes 45–60 minutes as a day procedure.